Skip Navigation

Cardiovascular Research 1997 36(3):453-459; doi:10.1016/S0008-6363(97)00204-6
© 1997 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sadoff, J. D.
Right arrow Articles by Weiss, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sadoff, J. D.
Right arrow Articles by Weiss, H. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Reduced myocardial cyclic GMP increases myocardial O2 consumption in control but not renal hypertension-induced cardiac hypertrophy

John D. Sadoff, Peter M. Scholz, James Tse and Harvey R. Weiss*

Heart and Brain Circulation Laboratory, Departments of Physiology and Biophysics, Anesthesia and Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854-5635, USA

* Corresponding author. Tel. (+1-732) 2354552; Fax (+1-732) 2355038.

Objectives: We tested the hypothesis that a reduction in myocardial cyclic GMP would increase myocardial O2 consumption and that renal hypertension (One Kidney-One Clip, 1K1C)-induced cardiac hypertrophy would change this relationship. Methods: Either vehicle or LY83583 (10–3 M, a guanylate cyclase inhibitor) was topically applied to the left ventricular surface of control or 1K1C anesthetized open-chest New Zealand white rabbits (N = 38). Coronary blood flow (radioactive microspheres) and O2 extraction (microspectrophotometry) were used to determine subepicardial (EPI) and subendocardial (ENDO) O2 consumption and myocardial cyclic GMP was determined by radioimmunoassay. Results: The heart weight/body weight ratio was greater in the 1K1C rabbits (3.16±0.20) than controls (2.58±0.08 g/kg). Systolic blood pressure was higher in 1K1C rabbits (116±8 mm Hg) than controls (80±6), but topical LY83583 had no significant hemodynamic effects. LY83583 significantly and similarly decreased EPI cyclic GMP in both control (7.9±1.2 to 6.0±1.0 pmol/g) and 1K1C (7.7±1.2 to 5.3±0.9) hearts and control ENDO (8.7±1.7 to 7.2±1.2) but not 1K1C ENDO (6.7±0.5 to 5.7±1.1). Myocardial O2 consumption was significantly increased in control with LY83583 (EPI 6.6±1.1 to 15.6±1.4 and ENDO 7.2±0.9 to 14.2±0.7 ml O2/min/100 g), but not in 1K1C hearts (EPI 12.1±1.0 to 12.9±1.2 or ENDO 11.4±0.7 to 12.9±0.9). Conclusions: Thus myocardial O2 consumption was only increased by LY83583 in control hearts, but LY83583 decreased cyclic GMP similarly in both the control and 1K1C EPI. This indicated, at least in the EPI, a dissociation of the inverse relationship between the myocardial level of cyclic GMP and O2 consumption in the 1K1C rabbit heart.

KEYWORDS Renal hypertension; Cardiac hypertrophy; Guanylate cyclase inhibition; Cyclic GMP; Coronary blood flow; Myocardial O2 consumption; Rabbit


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.